Eli Lilly wants to take big swings in Alzheimer’s, ALS, chronic pain and other difficult diseases after its success in ...
One participant lost 22% of her weight in nine months — substantially faster than the rate seen with approved GLP-1 drugs ...
A telehealth company partnered with a pharmacy that lacked a required license, raising doubts about the safety and efficacy ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback